{"id":"NCT04053270","sponsor":"Clinuvel Pharmaceuticals Limited","briefTitle":"Multicentre Phase III Erythropoietic Protoporphyria Study","officialTitle":"A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutanenous Bioresorbable CUV1647 Implants in Patients With Erythropoietic Protoporphyria (EPP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2009-12-09","completion":"2009-12-09","firstPosted":"2019-08-12","resultsPosted":"2019-10-10","lastUpdate":"2019-10-10"},"enrollment":100,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Erythropoietic Protoporphyria"],"interventions":[{"type":"DRUG","name":"Afamelanotide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"PLACEBO_COMPARATOR"}],"summary":"This was a phase III, multicentre, randomised, double-blind, placebo-controlled study, to evaluate the safety and efficacy of subcutaneous bioresorbable afamelanotide implants in patients with Erythropoietic Protoporphyria (EPP).\n\nThe study was conducted with two parallel study arms with crossover between treatments every 60 days.\n\nEligible patients were randomised to a treatment group, and received implants of active treatment (afamelanotide 16mg) or placebo, in an alternating crossover fashion according to the following dosing regime:\n\n* Group A was administered active implants on Days 0, 120, 240 and placebo implants on Days 60, 180, 300\n* Group B was administered placebo implants on Days 0, 120, 240 and active implants on Days 60, 180, 300","primaryOutcome":{"measure":"Cumulative Number of Days of Phototoxic Reactions (Study Efficacy Population)","timeFrame":"0-360 days or Early Termination","effectByArm":[{"arm":"Afamelanotide","deltaMin":39,"sd":null},{"arm":"Placebo","deltaMin":45,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["9521433"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":100},"commonTop":["Headache","Nausea","Nasopharyngitis","Diarrhoea","Fatigue"]}}